An Integrated Radio-immunological Approach

NCT ID: NCT05267509

Last Updated: 2026-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

31 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-23

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma, Malignant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with histologic confirmation of malignant glioma
* Patients must be age \>= 18 years
* Patients must be able to obtain an MRI scan with gadolinium contrast
* Patients must sign informed consent indicating that they are aware of the investigational nature of this study:
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Ospedaliero-Universitaria Careggi

OTHER

Sponsor Role collaborator

Azienda Ospedaliera di Padova

OTHER

Sponsor Role collaborator

Istituto Oncologico Veneto IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susanna Mandruzzato, PhD

Role: PRINCIPAL_INVESTIGATOR

Istituto Oncologico Veneto IOV-IRCCS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital

Florence, , Italy

Site Status

University Hospital

Padua, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/27

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glioma: Biomolecular Aspects
NCT05806619 COMPLETED
Hypofractionated Radiotherapy
NCT06740955 RECRUITING NA